natgillin/translations-raw huggingface dataset:
Poly (vinyl alcohol), partially hydrolysed (E1203), titanium dioxide (E171), talc (E553b), lecithin (derived from soya bean (E322)), xanthan gum (E415), iron oxide red (E172), iron oxide yellow (E172), sunset yellow FCF (E110).
Filmska obloga: delno hidroliziran polivinilalkohol (E1203), titanov dioksid (E171), smukec (E553b), lecitin (sojin (E322)), ksantanski gumi (E415), rdeči železov oksid (E172), rumeni železov oksid (E172), barvilo sončno rumeno FCF (E110).
Hepatobiliary disorders Transaminases increased common
Bolezni krvi in limfatičnega sistema zvišano število trombocitov pogosti
Lecithin (derived from soya bean (E322)) Xanthan gum (E415) Iron oxide red (E172) Iron oxide yellow (E172) Sunset yellow FCF (E110)
smukec (E553b), lecitin (sojin (E322)), ksantanski gumi (E415), rdeči železov oksid (E172), rumeni železov oksid (E172), sončno rumeno FCF (E110).
0.3% of patients receiving co-administration had clinically relevant increases in creatinine to values >200 µmol/l.
Klinično pomembno zvišanje ravni kreatinina nad > 200 μmol/l je imelo 0,3 % bolnikov, ki so sočasno prejemali obe zdravili.
In the larger study a reduction of 21% (90% CI 14%-27%) in AUC of SVA was observed after repeated co-administration of simvastatin 40 mg and fenofibrate 145 mg in the evening.
V večji študiji so po večkratnem sočasnem dajanju simvastatina 40 mg in fenofibrata 145 mg zvečer opazili 21-odstotno zmanjšanje AUC SVK (90-odstotni IZ 14 %-27 %).
The film-coated tablet (tablet) is a, oval, biconvex, brick red coloured 19.3 x 9.3 mm tablet with bevelled edges and the inscription 145/40 on one side and the Abbott logo on the other side.
Filmsko obložena tableta (tableta) je ovalna, bikonveksna, opečnato rdeče obarvana tableta velikosti 19,3 x 9,3 mm s posnetimi robovi in napisom 145/40 na eni strani in logotipom podjetja Abbott na drugi strani.
Increases in transaminase levels have been reported in some patients treated with simvastatin or fenofibrate.
Pri nekaterih bolnikih, zdravljenih s simvastatinom ali fenofibratom, so ugotovili zvišane ravni transaminaz.
Diabetes Mellitus**** not known
Presnovne in prehranske motnje sladkorna bolezen****
The film-coated tablet (tablet) is a, oval, biconvex, tan coloured 19.3 x 9.3 mm tablet with bevelled edges and the inscription 145/20 on one side and the Abbott logo on the other side.
Filmsko obložena tableta (tableta) je ovalna, bikonveksna, bež obarvana tableta velikosti 19,3 x 9,3 mm s posnetimi robovi in napisom 145/20 na eni strani in logotipom podjetja Abbott na drugi strani.
Cholib 145 mg/20 mg film-coated tablets fenofibrate/simvastatin
Cholib 145 mg/20 mg filmsko obložene tablete fenofibrat/simvastatin
Cholib 145 mg/40 mg film-coated tablets fenofibrate/simvastatin
Cholib 145 mg/40 mg filmsko obložene tablete fenofibrat/simvastatin
Each tablet contains 145 mg of fenofibrate and 40 mg of simvastatin
Ena tableta vsebuje 145 mg fenofibrata in 40 mg simvastatina
Alanine- aminotransferase increased
Bolezni jeter, žolčnika in žolčevodov zvišana raven alanin-aminotransferaze pogosti
Each tablet contains 145 mg of fenofibrate and 20 mg of simvastatin
Ena tableta vsebuje 145 mg fenofibrata in 20 mg simvastatina
Oval, biconvex, tan coloured, 19.3 x 9.3 mm film-coated tablet with bevelled edges and the inscription 145/20 on one side and the Abbott logo on the other side.
Ovalna, bikonveksna, bež filmsko obložena tableta velikosti 19,3 x 9,3 mm s posnetimi robovi in napisom 145/20 na eni strani in logotipom podjetja Abbott na drugi strani.
Each tablet contains 145 mg of fenofibrate and 40 mg of simvastatin.
Ena tableta vsebuje 145 mg fenofibrata in 40 mg simvastatina.
• increase in “urea” - produced by the kidneys - shown in tests
• zvišanje ravni „sečnine“ (snovi, ki jo tvorijo ledvice), kar pokažejo preiskave,
Oval, biconvex, brick red coloured, 19.3 x 9.3 mm film-coated tablet with bevelled edges and the inscription 145/40 on one side and the Abbott logo on the other side.
Ovalna, bikonveksna, opečno rdeča filmsko obložena tableta velikosti 19,3 x 9,3 mm s posnetimi robovi in napisom 145/40 na eni strani in logotipom podjetja Abbott na drugi strani.
Each tablet contains 145 mg of fenofibrate and 20 mg of simvastatin.
Ena tableta vsebuje 145 mg fenofibrata in 20 mg simvastatina.
The risk of myopathy/rhabdomyolysis is increased by concomitant administration of ciclosporin with simvastatin.
Pri sočasni uporabi ciklosporina in simvastatina se poveča tveganje za miopatijo/rabdomiolizo.
One film-coated tablet contains 145 mg of fenofibrate and 40 mg of simvastatin.
KAKOVOSTNA IN KOLIČINSKA SESTAVA Ena filmsko obložena tableta vsebuje 145 mg fenofibrata in 40 mg simvastatina.
Interacting substances
SEZNAM POMOŽNIH SNOVI
The primary efficacy criterion was superiority of the combination fenofibrate 145 and simvastatin 20 mg versus simvastatin 40 mg on TG decrease and HDL-C increase and non-inferiority for LDL-C decrease at 12 weeks.
V študiji 0501 so v 24-tedenskem dvojno slepem obdobju vrednotili dva različna odmerka kombinacije fenofibrata in simvastatina v primerjavi s simvastatinom 40 mg. Primarno merilo učinkovitosti je bila boljša učinkovitost kombinacije fenofibrata 145 mg in simvastatina 20 mg v primerjavi s simvastatinom 40 mg pri znižanju TG in zvišanju HDL-holesterola ter neinferiornost pri znižanju LDL-holesterola po 12 tednih.
Your doctor should do a blood test before you start taking Cholib.
Pred začetkom jemanja zdravila Cholib boste morali opraviti krvno preiskavo, da vaš zdravnik preveri delovanje jeter.
The risk of myopathy and rhabdomyolysis is increased by concomitant administration of danazol with simvastatin.
Pri sočasni uporabi danazola in simvastatina se poveča tveganje za miopatijo in rabdomiolizo.
The risk of myopathy including rhabdomyolysis may be increased by the concomitant administration of systemic fusidic acid with statins.
Pri sočasni sistemski uporabi fusidne kisline in statinov se lahko poveča tveganje za miopatijo, vključno z rabdomiolizo.
uncommo n
n.r.
The European Commission granted a marketing authorisation valid throughout the European Union for Brilique on 3 December 2010.
Evropska komisija je dovoljenje za promet z zdravilom Brilique, veljavno po vsej Evropski uniji, izdala 3. decembra 2010.
It is available as tablets (60 and 90 mg).
Na voljo je v obliki tablet (60 in 90 mg).
The full EPAR for Brilique can be searched for on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Brilique je na voljo na spletni strani agencije website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Other information about Brilique
Druge informacije o zdravilu Brilique
It must also not be used in patients taking other medicines which have a strong blocking effect on one of the liver enzymes (CYP3A4).
Prav tako ga ne smejo uporabljati bolniki, ki jemljejo druga zdravila z močnim zaviralnim učinkom na enega od jetrnih encimov (CYP3A4).
The CHMP decided that Brilique's benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Brilique večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
For more information about treatment with Brilique, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Brilique preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What is the risk associated with Brilique?
Kakšna tveganja so povezana z zdravilom Brilique?
This is a summary of the European public assessment report (EPAR) for Brilique.
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Brilique.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Brilique.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The patients also took aspirin and were treated for up to 3 years.
Bolniki so jemali tudi aspirin in so se zdravili največ tri leta.
What benefit has Brilique shown during the studies?
Kakšne koristi je zdravilo Brilique izkazalo med študijami?
Brilique must not be used in patients who have severe liver disease or are currently bleeding, or in patients who have had bleeding within the brain.
Zdravila Brilique ne smejo uporabljati bolniki s hudim obolenjem jeter ali ki trenutno krvavijo in bolniki, ki so imeli krvavitev v možganih.
Why has Brilique been approved?
Zakaj je bilo zdravilo Brilique odobreno?
The patients also took aspirin and were treated for up to a year.
Bolniki so jemali tudi aspirin in so se zdravili največ eno leto.
The doctor may, for health reasons, tell them not to take aspirin.
Zaradi zdravstvenih razlogov pa jim lahko zdravnik jemanje aspirina odsvetuje.
These are medicines such as ketoconazole (used to treat fungal infections), clarithromycin (an antibiotic), atazanavir and ritonavir (medicines used in HIV-positive patients) and nefazodone (used to treat depression).
To so zdravila, kot so ketokonazol (za zdravljenje glivičnih okužb), klaritromicin (antibiotik), atazanavir in ritonavir (zdravili za zdravljenje bolnikov, okuženih z virusom HIV) in nefazodon (za zdravljenje depresije).
Brilique is a medicine that contains the active substance ticagrelor.
Brilique je zdravilo, ki vsebuje zdravilno učinkovino ticagrelor.
Ticagrelor stops the platelets aggregating by blocking the action of a substance called ADP when it attaches to the surface of the platelets.
Ticagrelor prepreči agregacijo trombocitov tako, da zavira delovanje snovi, imenovane ADP, ko se pritrdi na površino trombocitov.
The main measure of effectiveness for both studies was based on the number of patients having another heart attack, a stroke or dying from a cardiovascular disease.
Glavno merilo učinkovitosti je pri obeh študijah temeljilo na številu bolnikov, ki so doživeli še en srčni infarkt ali kap oziroma so umrli zaradi srčno-žilne bolezni.
The most common side effects with Brilique (seen in more than 1 patient in 10) are dyspnoea (difficulty breathing), bleeding and raised uric acid level in the blood.
Najpogostejši neželeni učinki zdravila Brilique (opaženi pri več kot 1 bolniku od 10) so dispneja (težave z dihanjem), krvavitve in povečane ravni sečne kisline v krvi.
For longer treatment, the dose of Brilique should be reduced to one 60-mg tablet twice a day.
Pri daljšem zdravljenju je treba odmerek zdravila Brilique zmanjšati na eno 60-miligramsko tableto dvakrat na dan.
It is used in adults with acute coronary syndrome, a group of conditions in which blood flow in the vessels supplying the heart is blocked so heart tissue cannot work properly or dies, and which includes heart attack and unstable angina (a severe type of chest pain).
Uporablja se pri odraslih z akutnim koronarnim sindromom, tj. skupino obolenj, pri katerih je dotok krvi v žilah, ki oskrbujejo srce, zavrt, zaradi česar srčno tkivo ne more pravilno delovati ali odmre, in ki zajema srčni infarkt in nestabilno angino pektoris (hudo obliko bolečine v prsih).
Brilique is used together with aspirin (acetylsalicylic acid) to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries) such as heart attacks or strokes.
Zdravilo Brilique se uporablja skupaj z aspirinom (acetilsalicilno kislino) za preprečevanje aterotrombotičnih dogodkov (težav zaradi krvnih strdkov in zatrditve arterij), kot sta srčni infarkt ali kap.
This stops the platelets becoming ‘sticky', reducing the risk of a blood clot forming and helping to prevent a stroke or another heart attack.
Zaradi tega trombociti ne postanejo „lepljivi“, kar zmanjša tveganje za nastanek krvnega strdka in pripomore k preprečevanju kapi ali drugega srčnega infarkta.
In the first main study (in patients with acute coronary syndrome), 9.3% of the patients taking Brilique had another heart attack, stroke or died from a cardiovascular disease compared with 10.9% of patients taking clopidogrel.
V prvi glavni študiji (pri bolnikih z akutnim koronarnim sindromom) je 9,3 % bolnikov, ki so jemali zdravilo Brilique, doživelo še en srčni infarkt ali kap ali pa so umrli zaradi srčno-žilne bolezni, v primerjavi z 10,9 % bolnikov, ki so jemali klopidogrel.
Brilique is also used in adults who had a heart attack a year or more ago and are at a high risk of an atherothrombotic event.
Zdravilo Brilique se uporablja tudi pri odraslih, ki so doživeli srčni infarkt pred enim letom ali več, in pri katerih obstaja veliko tveganje za nastanek aterotrombotičnih dogodkov.
The CHMP considered that in patients with acute coronary artery syndrome, Brilique at a dose of 90 mg twice daily and given with aspirin, reduces the risk of atherothrombotic events such as heart attack, stroke and death from a cardiovascular event.
Menil je, da pri bolnikih z akutnim koronarnim sindromom zdravilo Brilique v 90-miligramskem odmerku, vzetem dvakrat na dan skupaj z aspirinom, zmanjša tveganje za nastanek aterotrombotičnih dogodkov, kot so srčni infarkt, kap in smrt zaradi srčno-žilne bolezni.
The active substance in Brilique, ticagrelor, is an inhibitor of platelet aggregation.
Zdravilna učinkovina zdravila Brilique, ticagrelor, je zaviralec agregacije trombocitov.
Brilique was compared with clopidogrel (another inhibitor of platelet aggregation) in a main study involving over 18,000 adults who had had a heart attack or had unstable angina.
Zdravilo Brilique so primerjali s klopidogrelom (drugim zaviralcem agregacije trombocitov) v glavni študiji, v katero je bilo vključenih več kot 18 000 odraslih z nestabilno angino pektoris ali po srčnem infarktu.
Patients took Brilique twice a day in a dose of either 60 mg or 90 mg.
Bolniki so zdravilo Brilique jemali dvakrat na dan v 60-miligramskem oziroma 90-miligramskem odmerku.
In another main study, Brilique was compared with placebo (a dummy treatment) in over 21,000 adults who had a heart attack one to three years previously and were at high risk of an atherothrombotic event.
V drugi glavni študiji so zdravilo Brilique primerjali s placebom (zdravilom brez zdravilne učinkovine) pri več kot 21 000 odraslih, ki doživeli srčni infarkt eno do tri leta prej in pri katerih je obstajalo veliko tveganje za nastanek aterotrombotičnih dogodkov.
For the full list of restrictions with Brilique, see the package leaflet.
Za celoten seznam omejitev pri uporabi zdravila Brilique glejte navodilo za uporabo.
When the blood clots, this is due to cell fragments in the blood called platelets aggregating (sticking together).
Strjevanje krvi je posledica agregacije (zlepljanja) celičnih delcev v krvi, imenovanih trombociti.
How has Brilique been studied?
Kako je bilo zdravilo Brilique raziskano?
Brilique was shown to be beneficial to patients who have had a heart attack or unstable angina.
Zdravilo Brilique se je izkazalo kot koristno za bolnike z nestabilno angino ali po srčnem infarktu.
For the full list of all side effects reported with Brilique, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Brilique, glejte navodilo za uporabo.
In the second main study (in patients with a history of the heart attack), 7.8% of patients taking Brilique 60 mg twice a day had another heart attack, stroke or died from cardiovascular disease compared with 9.0% of patients taking placebo.
V drugi glavni študiji (pri bolnikih, ki so doživeli srčni infarkt ali kap) je 7,8 % bolnikov, ki so jemali zdravilo Brilique v 60-miligramskem odmerku dvakrat na dan, doživelo še en srčni infarkt ali kap ali pa so umrli zaradi srčno-žilne bolezni, v primerjavi z 9,0 % bolnikov, ki so jemali klopidogrel.
How does Brilique work?
Kako zdravilo Brilique deluje?
What is Brilique used for?
Za kaj se zdravilo Brilique uporablja?
For patients who have had a heart attack a year or more ago (but less than 2 years ago) and are at high risk of an atherothrombotic event, the dose of Brilique is one 60-mg tablet twice a day.
Odmerek pri bolnikih, ki so doživeli srčni infarkt pred enim letom ali več (vendar pred manj kot dvema letoma) in pri katerih obstaja veliko tveganje za nastanek aterotrombotičnih dogodkov, je ena
For patients with acute coronary syndrome, the starting dose of Brilique is two 90-mg tablets taken at once, followed by a regular dose of one 90-mg tablet twice a day.
Začetni odmerek zdravila Brilique pri bolnikih z akutnim koronarnim sindromom sta dve 90-miligramski tableti, ki ju bolnik vzame hkrati, sledi pa redni odmerek ene 90-miligramske tablete dvakrat na dan. Zdravljenje z zdravilom Brilique lahko traja eno leto, razen če zdravnik presodi, da ga je treba prekiniti prej.
What is Brilique?
Kaj je zdravilo Brilique?
How is Brilique used?
Kako se zdravilo Brilique uporablja?
Benefit regarding heart attack, stroke and death from a cardiovascular event has also been shown in patients who had a heart attack at least one year ago and have a high risk of an atherothrombotic event and a lower 60 mg dose twice daily dose is recommended for these patients.
Prav tako so bile pri bolnikih, pri so doživeli srčni infarkt pred najmanj enim letom in pri katerih obstaja veliko tveganje za nastanek aterotrombotičnih dogodkov opažene koristi v zvezi s srčnim infarktom, kapjo in smrtjo zaradi srčno-žilne bolezni.
Previously known as Zylagren
Prej znano kot Zylagren
The European Commission granted a marketing authorisation valid throughout the EU for Zylagren on 21 September 2009.
Evropska komisija je dovoljenje za promet z zdravilom Zylagren, veljavno po vsej Evropski uniji, izdala 21. septembra 2009.
The full EPAR for Clopidogrel BGR can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za Clopidogrel BGR je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This is a summary of the European public assessment report (EPAR) for Clopidogrel BGR.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Clopidogrel BGR.
For more information about treatment with Clopidogrel BGR, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Clopidogrel BGR preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The name of the medicine was changed to Clopidogrel BGR on 14 July 2014.
Ime zdravila je bilo 14. julija 2014 spremenjeno v Clopidogrel BGR.
The standard dose of Clopidogrel BGR is one 75 mg tablet once a day.
Standardni odmerek zdravila Clopidogrel BGR je ena 75-miligramska tableta enkrat na dan.
This means that Clopidogrel BGR is similar to a ‘reference medicine' already authorised in the European Union (EU) called Plavix.
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Plavix.
Clopidogrel BGR is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries).
Zdravilo Clopidogrel BGR se uporablja pri odraslih za preprečevanje aterotrombotičnih dogodkov (težav, ki jih povzročajo krvni strdki in otrdelost krvnih žil).
Clopidogrel BGR can be given to the following groups of patients:
Zdravilo Clopidogrel BGR se lahko daje naslednjim skupinam bolnikov:
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Clopidogrel BGR.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The Committee recommended that Clopidogrel BGR be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Clopidogrel BGR izda dovoljenje za promet.
Because Clopidogrel BGR is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Ker je zdravilo Clopidogrel BGR generično zdravilo in je biološko enakovredno referenčnemu zdravilu, velja, da so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
The CHMP concluded that, in accordance with EU requirements, Clopidogrel BGR has been shown to have comparable quality and to be bioequivalent to Plavix.
CHMP je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Clopidogrel BGR primerljivo raven kakovosti kot zdravilo Plavix ter da mu je biološko enakovredno.
Clopidogrel BGR can be started between a few days and 35 days after the attack;
Zdravilo Clopidogrel BGR se lahko začne jemati od nekaj dni po napadu do 35 dni po njem;
Clopidogrel stops the platelets aggregating by blocking a substance called ADP from attaching to a special receptor on their surface.
Klopidogrel prepreči zlepljanje trombocitov tako, da snovi, imenovani ADP, preprečuje, da bi se vezala na posebne receptorje na njihovi površini.
• patients with peripheral arterial disease (problems with blood flow in the arteries);
• bolnikom s periferno arterijsko boleznijo (težavami s pretokom krvi v arterijah); Izdaja zdravila je le na recept.
What are the benefits and risks of Clopidogrel BGR?
Kakšne so koristi in tveganja, povezani z zdravilom Clopidogrel BGR?
Because Clopidogrel BGR is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix.
Ker je zdravilo Clopidogrel BGR generično zdravilo, so bile študije pri ljudeh omejene na preizkuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Plavix.
Clopidogrel BGR can be started between seven days and six months after the stroke;
Zdravilo Clopidogrel BGR se lahko začne jemati od sedem dni po napadu do šest mesecev po njem;
Clopidogrel BGR is a ‘generic medicine'.
Clopidogrel BGR je „generično zdravilo“.
Other information about Clopidogrel BGR
Druge informacije o zdravilu Clopidogrel BGR
Clopidogrel BGR is a medicine that contains the active substance clopidogrel.
Clopidogrel BGR je zdravilo, ki vsebuje zdravilno učinkovino klopidogrel.
The active substance in Clopidogrel BGR, clopidogrel, is an inhibitor of platelet aggregation.
Zdravilna učinkovina v zdravilu Clopidogrel BGR, klopidogrel, je zaviralec agregacije trombocitov.
Why has Clopidogrel BGR been approved?
Zakaj je bilo zdravilo Clopidogrel BGR odobreno?
What is Clopidogrel BGR?
Kaj je zdravilo Clopidogrel BGR?
What is Clopidogrel BGR used for?
Za kaj se zdravilo Clopidogrel BGR uporablja?
How has Clopidogrel BGR been studied?
Kako je bilo zdravilo Clopidogrel BGR raziskano?
How is Clopidogrel BGR used?
Kako se zdravilo Clopidogrel BGR uporablja?
How does Clopidogrel BGR work?
Kako zdravilo Clopidogrel BGR deluje?
Date of first authorisation: 8 March 2002 Date of latest renewal: 20 March 2007
Datum prve odobritve: 8. marec 2002 Datum zadnjega podaljšanja: 20. marec 2007
The available medical guidelines should also be taken into account.
Upoštevati je treba tudi razpoložljive medicinske smernice.
Additional information on MAS is provided below.
Dodatne informacije o MAS so na voljo spodaj.
The instructions for use and handling are given in section 6.6.
Navodila za uporabo in ravnanje so podana v poglavju 6.6.
Elderly population (≥ 65 years)
Starejša populacija (≥ 65 let)
A risk to the newborns/ infants cannot be excluded.
Tveganja za dojenega novorojenca/otroka ne moremo izključiti.
This might increase the risk of you getting an infection.
Zaradi tega se lahko poveča nevarnost, da boste dobili okužbo.
ISRs typically appear within 2 weeks of therapy and disappear within 4-6 weeks.
ISR se po navadi pojavijo v 2 tednih zdravljenja in izginejo v 4-6 tednih.
How do you give your injection?
Kako si daste injekcijo?